Cargando…
Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review
BACKGROUND: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a relatively novel class of oral medications for the treatment of Type 2 DM with a generally acceptable safety profile. However, these agents have been associated with rare events of a serious and potentially life-threatening compli...
Autores principales: | Sampani, Erasmia, Sarafidis, Pantelis, Dimitriadis, Chrysostomos, Kasimatis, Efstratios, Daikidou, Dimitra, Bantis, Konstantinos, Papanikolaou, Alexios, Papagianni, Aikaterini |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364613/ https://www.ncbi.nlm.nih.gov/pubmed/32669085 http://dx.doi.org/10.1186/s12882-020-01930-6 |
Ejemplares similares
-
A Rare Case of Extensive Eggshell Intestinal Wall Peritoneal Calcification in a Long-Term Continuous Peritoneal Dialysis Patient
por: Sampani, Erasmia, et al.
Publicado: (2022) -
CD28null and Regulatory T Cells Are Substantially Disrupted in Patients with End-Stage Renal Disease Due to Diabetes Mellitus
por: Sampani, Erasmia, et al.
Publicado: (2021) -
Empagliflozin: Euglycemic and hyperglycaemic diabetic ketoacidosis: case report
Publicado: (2021) -
Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020) -
SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
por: Thomas, Mathew, et al.
Publicado: (2019)